NCCN Guidelines for Patients
Peripheral T-cell Lymphoma, Version 1.2016
Overview of cancer treatments Targeted therapy
Targeted therapy is a class of drugs that stops the
action of molecules that helps cancer cells grow. It is
less likely to harm normal cells than chemotherapy.
There are 3 targeted therapies that are used to treat
peripheral T-cell lymphoma. These treatments are
briefly described next. Some side effects are listed.
Ask your treatment team for a full list of common and
rare side effects. In Part 4, information on who should
receive these drugs is provided.
Monoclonal antibodies are man-made antibodies that
attach to proteins on cancer cells. The monoclonal
antibody used to treat peripheral T-cell lymphoma
attach to antigens. When antibodies are attached to
antigens on a cell, the cell is marked to be destroyed
by your immune system.
Alemtuzumab is a monoclonal antibody that attaches
to a molecule called CD52. CD52 is found on
peripheral T-cell lymphoma cells, healthy B-cells and
T-cells, as well as other cells. Alemtuzumab is rarely
used to treat peripheral T-cell lymphoma.
Alemtuzumab is a liquid that will be slowly injected
into your vein. It may take up to two hours to get
the full dose. Alemtuzuamb can also be given as an
injection under the skin. Alemtuzumab is often given
three times a week for 12 weeks.
Common side effects include an allergic reaction
when receiving the medicine. Also, you may feel
nausea, vomit, get diarrhea, and have trouble
sleeping. Blood counts are often low when taking
this medicine. Taking alemtuzumab will increase
your chances of getting a cytomegalovirus or other
DNA is tightly wrapped around proteins called
histones to form chromosomes. HDAC (
etylase) removes a chemical group from
histones so that DNA can wrap more tightly. HDAC
inhibitors enter cells and block the action of HDAC.
Blocking can turn on genes that were shut down
by cancer and lead to cell death. Belinostat is an
HDAC inhibitor. It is used to treat some subtypes of
peripheral T-cell lymphoma cells.
Belinostat is a liquid that will be slowly injected into
your vein for about 30 minutes. It is given during the
first 5 days of a 21-day cycle. Your doctor will discuss
with you how many cycles are needed.
Common side effects include nausea, vomiting,
fatigue, fever, low numbers of red blood cells. It may
also cause liver damage and increase your chance
of getting an infection. Belinostat can harm unborn
Brentuximab vedotin contains a monoclonal antibody
that delivers cell-specific chemotherapy. On the
surface of some peripheral T-cell lymphomas are
proteins called CD30. Brentuximab attaches to CD30
and enters cancer cells. Once inside, it releases the
chemotherapy. By targeting only cells with CD30
proteins, fewer normal cells are harmed.
Brentuximab vedotin is slowly injected into a vein for
about 30 minutes. It is often given every 3 weeks. The
most common side effects include fatigue, low blood
counts, tingling in hands and feet, nausea, diarrhea,
fever, rash, and lung infections. Rare but severe side
effects include brain infection, serious disorder of skin
and mucous membranes, and kidney problems.